Dr Sergey Tumanov is a bioanalytical chemist from Belarussian State University, Minsk.
In 2011 he undertook his PhD at University of Auckland, New Zealand, where he utilised a metabolomics approach to study yeast metabolism during fermentation. In 2014, Dr Tumanov joined the Beatson Institute for Cancer Research in Glasgow, UK, where he worked as a postdoctoral research scientist on the utilization of 13C- and 2H-tracing and mass spectrometry-based -omics techniques to study lipid metabolism in cancer.
In 2018, he joined Professor Roland Stocker’s laboratory at the Victor Chang Cardiac Research Institute, where he worked with an in vivo tandem stenosis model of plaque instability on the genetic background of ApoE deficiency.
Dr Tumanov is Project Lead for establishing Australia’s first fluxomics facility for cardiovascular disease. He has been working with HRI since 2020. His previous research has focused on understanding the role of myeloperoxidase in causing unstable atherosclerotic plaque; understanding the metabolic alterations that lead to the formation of unstable atherosclerotic plaque; and discovering new molecular imaging targets and biomarkers that distinguish stable from unstable atherosclerotic plaque utilising a multi-omics approach, ie, metabolomics, lipidomics, proteomics and fluxomics.